Bone Metastasis in Solid Tumors Epidemiology

Bone Metastasis in Solid Tumour Trends

• According to epidemiological studies, bone metastasis is one of the most common complications of advanced solid tumors, occurring most frequently in patients with breast, prostate, lung, kidney, and thyroid cancers. The skeleton represents the third most common site of metastatic spread after the lungs and liver.
• As reported by multiple oncology studies, approximately 65–75% of patients with advanced breast or prostate cancer eventually develop bone metastases, making these malignancies the largest contributors to the global burden of metastatic bone disease.
• Epidemiological analyses indicate that 30–40% of patients with advanced lung cancer develop bone metastases during the course of their disease, while clinically significant skeletal involvement is also observed in renal cell carcinoma, thyroid cancer, and other solid tumors.
• Improvements in cancer diagnosis, treatment, and survival have contributed to a growing prevalence of bone metastases, as patients are living longer with advanced disease and therefore remain at increased risk of developing metastatic skeletal complications.
• Bone metastases are associated with substantial morbidity, including skeletal-related events (SREs) such as pathological fractures, spinal cord compression, hypercalcemia, and the need for radiation therapy or surgery to the bone, all of which significantly impair patient quality of life.
• The incidence of bone metastases varies by tumor type and disease stage, with advanced and metastatic cancers demonstrating the highest rates of skeletal involvement. The risk increases with prolonged survival, higher tumor burden, and aggressive disease biology.
• Bone metastases affect both males and females, although distribution varies according to the underlying primary cancer. Breast cancer remains the predominant source of bone metastases in women, whereas prostate cancer represents the leading cause among men.
• Epidemiological trends indicate that the population living with bone metastases will continue to expand throughout the forecast period, driven by continued improvements in cancer survival and broader access to oncology care across major markets.
• Ongoing research into tumor–bone interactions and metastatic biology is improving understanding of disease progression and supporting the development of targeted therapeutic strategies aimed at reducing the long-term burden of bone metastatic disease.

Bone Metastasis in Solid Tumour Epidemiology Forecast in the United States

• 2025 Diagnosed Prevalent Cases of Bone Metastasis in Solid Tumour: ~XXXX
• 2036 Projected Diagnosed Prevalent Cases of Bone Metastasis in Solid Tumour: ~XXXX
• Bone Metastasis in Solid Tumour Growth Rate (2026–2036): XX% CAGR

DelveInsight's ‘Bone Metastasis in Solid Tumour Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the Bone Metastasis in Solid Tumour, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France), and the United Kingdom, and Japan.

Bone Metastasis in Solid Tumour Understanding and Diagnosis Algorithm

Bone Metastasis in Solid Tumour Overview and Diagnosis

Bone metastasis in solid tumors occurs when cancer cells spread from a primary tumor to the bone, forming secondary malignant lesions within the skeletal system. It is a common complication of advanced cancers such as breast, prostate, lung, renal cell carcinoma, and thyroid cancer. The process involves complex tumor–bone interactions that drive osteoclastic or osteoblastic activity, leading to bone destruction and remodeling. Bone metastases can result in significant morbidity through skeletal-related events, including pain, pathological fractures, spinal cord compression, hypercalcemia, and reduced mobility, severely impacting quality of life and increasing healthcare burden. Although generally incurable, advances in systemic therapies and supportive care have improved disease control and survival outcomes.

Bone Metastasis in Solid Tumour Diagnosis

Diagnosis is based on a combination of clinical evaluation, imaging studies, laboratory tests, and, when needed, histopathological confirmation. Patients typically present with persistent bone pain, fractures, neurological symptoms, or hypercalcemia. Imaging modalities such as bone scintigraphy, CT, MRI, PET, and PET/CT are key for detecting and characterizing metastatic lesions. Laboratory markers, including alkaline phosphatase, calcium, and tumor-specific biomarkers, provide supportive evidence of disease burden. In selected cases, a bone biopsy is performed to confirm metastasis and determine the primary tumor origin. Early and accurate diagnosis is essential for timely treatment, prevention of skeletal complications, and improved clinical outcomes.

Further details are provided in the report.

Bone Metastasis in Solid Tumour Epidemiology

Key Findings from Bone Metastasis in Solid Tumour Epidemiological Analysis and Forecast 

• According to Shibata et al. (2016), a study of autopsy cases from the Shikoku Cancer Center in Japan reported that bone metastasis frequencies varied by cancer type, reaching as high as 75% in breast and prostate cancers and as low as 22% in stomach and colon cancers.
• As per the study by Huang et al. (2020), the rate of bone metastases is 23.19% in SCLC, 22.50% in NSCLC (NOS/others), 20.28% in ADC, 8.44% in squamous cell carcinoma of the lung (SCC), and 4.11% in bronchioloalveolar carcinoma [NSCLC (BAC)]. 
• According to the American Cancer Society (ACS), about 400,000 new cases of malignant bone metastasis are diagnosed in the United States each year. 
• Metastatic bone disease is commonly observed in breast (70%), prostate (85%), lung (40%), and kidney (40%) cancers, as reported by Coleman et al. (2020).
• In addition, as per ACS, the incidence of advanced malignant tumors with bone metastasis is 30–75%, especially common in patients with advanced prostate cancer and breast cancer. 
• According to Hernandez et al. (2015), approximately 330,000 patients aged 18 years and older were living with solid tumors and bone metastases in 2012, including 168,063 Medicare fee-for-service patients and 162,239 others.

Scope of the Report

• The report covers a segment of an executive summary, a descriptive overview of Bone Metastasis in Solid tumour, explaining its causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

Bone Metastasis in Solid Tumour Patient Population Forecast

Report Key Strengths

• Epidemiology‑based (epi‑based) Bottom‑up Forecasting
• 11-year Forecast 
• Patient Burden Trends (by geography)

FAQs

• What are the disease risks, burdens, and unmet needs of Bone Metastasis in Solid tumour? What will be the growth opportunities across the 7MM concerning the patient population with Bone Metastasis in Solid tumour?
• What is the historical and forecasted Bone Metastasis in Solid tumour patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders’ perspectives on the diagnostic challenges to overcome barriers in the future.
• Detailed insights into various factors hampering disease diagnosis and other existing diagnostic challenges.